Jack, 28 - (no city), reported fewer migraine days after several weeks of treatment. He noticed evening tiredness at first and avoided driving until he knew how strongly the tablets affected him.
Several weeks 26 Oct 2026
Sibelium
Sibelium is intended for people who need prevention of recurrent migraine or selected vestibular symptoms. Its flunarizine-based action helps reduce excessive calcium activity, so benefits are…
Sibelium is intended for people who need prevention of recurrent migraine or selected vestibular symptoms. Its flunarizine-based action helps reduce excessive calcium activity, so benefits are assessed over time rather than during a single acute attack.
Product information
Flunarizine, the active ingredient of Sibelium, is a calcium channel blocker used mainly to prevent migraine attacks and manage selected vestibular disorders. It reduces excessive calcium-related cellular activity, helping limit migraine recurrence and balance symptoms rather than providing immediate relief during an acute attack.
Ingredients
Sibelium contains flunarizine, a selective calcium channel blocker with neurological effects. It is supplied as oral tablets and is used as a preventive treatment, not as a rapid painkiller for an attack that has already started.
Therapeutic indications
Primary Medical Indications
Sibelium is used mainly for migraine prevention. It may be considered when migraine attacks are frequent, prolonged, disabling, or poorly controlled with acute treatment alone. The aim is to reduce the number of attacks and lessen their severity over a sustained treatment period.
Flunarizine may also be used for vertigo associated with vestibular disorders. Vertigo is a false sensation of movement, such as spinning or tilting. Vestibular symptoms can occur with nausea, imbalance, visual discomfort, or difficulty walking.
This treatment is not intended to stop every migraine immediately. Preventive therapy is judged by the pattern of attacks across several weeks, not by the response to one tablet.
Clinical guidance from NICE and the American Headache Society places migraine prevention alongside sleep regularity, hydration, trigger management, and appropriate acute treatment. Flunarizine may be useful when a preventive calcium-channel-blocking approach fits the person’s medical history, but its sedating and movement-related adverse effects can limit treatment [2].
Directions for use
The amount taken per intake is set individually for each person. A fixed dose should not be selected solely from general internet information.
Tablet Strengths and Administration
Sibelium is an oral tablet. The amount per intake is selected individually rather than being one fixed number for every person, so the prescribed instructions take priority over a standard internet dosage.
Administration Principles
- Take the tablet by mouth at the prescribed frequency.
- Use it consistently at the same time when possible.
- Swallow the tablet with water unless a prescriber has given different instructions.
- Do not increase the amount because a migraine occurs.
- Do not stop long-term treatment abruptly without a planned review.
- If a dose is missed, take it when remembered unless the next scheduled dose is near.
- Do not double the next dose to compensate for a missed dose.
The treatment period depends on the reason for use and the response. Migraine prevention often requires enough time to compare attack patterns before a decision is made about continuation. Vertigo treatment also requires review because dizziness can have several causes.
Avoid driving or operating machinery until you know whether Sibelium causes drowsiness, slowed reactions, or impaired coordination. Alcohol may intensify sedation and can make balance symptoms harder to assess.
When not to use it
- Current depression or a previous depressive episode linked to medicines.
- Parkinson’s disease, parkinsonism, tremor, rigidity, or unexplained slowed movement.
- A previous serious reaction to flunarizine.
- Significant daytime sleepiness or recurrent falls.
- Pregnancy or breastfeeding.
- Liver disease requiring medication review.
- Use of sedating medicines, sleeping tablets, opioid pain medicines, or alcohol.
- Treatment with medicines that can worsen movement symptoms or depression.
When this is not for you
Sibelium may not be right for you if you have depression, Parkinson’s disease or other movement problems, troublesome sleepiness, or repeated falls. You should also speak with a doctor before using it if you are pregnant or breastfeeding, have liver disease, or take medicines, sleeping tablets, opioid pain medicines, or alcohol that can make you drowsy. Seek urgent medical attention for severe mood deterioration, suicidal thoughts, marked rigidity, uncontrolled movements, fainting, or a serious allergic reaction involving facial swelling or breathing difficulty.
Unwanted effects
Flunarizine can cause drowsiness, fatigue, increased appetite, weight gain, and low mood. Some people develop gastrointestinal discomfort or dry mouth. Hair loss, known clinically as alopecia, has also been reported and may improve after treatment is stopped.
The risk of adverse effects can increase during prolonged use. A person who feels unusually slowed, emotionally flat, or physically unsteady should report those changes during a medication review. Daytime somnolence can be easy to dismiss as poor sleep, especially when treatment is started during a stressful period.
Other clinically significant reactions include extrapyramidal symptoms, such as tremor, stiffness, slowed movement, or restlessness. Depression can occur or worsen in susceptible individuals. These effects require prompt medical assessment because they may indicate that continued treatment is unsuitable.
Hair shedding may appear gradually rather than immediately. Photographing the hair parting or noting increased hair in the shower can help establish whether the change is continuing, although treatment decisions should be based on clinical assessment.
Mechanism of action
Flunarizine reduces calcium entry into certain cells, which may help moderate processes involved in migraine and vestibular dysfunction [1].
A calcium channel blocker limits the movement of calcium through cell membranes. In neurological conditions, excessive calcium activity can contribute to nerve excitability and vascular changes. Flunarizine also has antihistaminic properties, which may contribute to its effects on vestibular symptoms.
Pharmacological Classification
Flunarizine belongs to the calcium channel blocker group and is used in neurology rather than primarily for heart or blood-pressure treatment. Its clinical role differs from that of medicines designed to relax airway muscle, control cardiac rhythm, or lower blood pressure.
The medicine acts gradually. Its benefit is assessed by tracking the frequency, severity, and duration of migraine or vestibular episodes over time. A diary can help show whether the treatment is reducing attacks rather than simply changing symptoms from one day to the next.
Common mistakes
Several habits can make Sibelium appear less useful or increase avoidable problems:
- Taking extra tablets when a migraine begins.
- Stopping after a few days because prevention does not feel immediate.
- Continuing despite worsening depression or new movement symptoms.
- Combining it with alcohol or several sedating products.
- Forgetting to record migraine days and relying on memory.
- Changing the timing repeatedly because of tiredness.
- Treating every episode of vertigo as the same condition.
- Driving before knowing how the tablet affects alertness.
- Ignoring appetite and weight changes during long-term treatment.
- Assuming a missed dose should be replaced with a double dose.
A frequent mistake is judging the treatment only by pain intensity. Fewer attacks, shorter attacks, less nausea, and reduced need for rescue treatment may all represent meaningful improvement.
Another is overlooking mood changes. Fatigue is sometimes expected, but persistent low mood is a separate warning sign and should be reported promptly.
Comparison
Comparison with Neurological Treatment Approaches
Neurological treatments differ by mechanism and by the symptom they target. Flunarizine is used mainly for prevention, while other categories may focus on acute migraine relief, blood-pressure pathways, or inner-ear symptoms.
| Treatment approach | Main pharmacological role | Practical limitation |
|---|---|---|
| Flunarizine | Preventive calcium-channel-blocking approach for migraine and selected vestibular symptoms | Sleepiness, weight gain, low mood, and movement symptoms may limit use |
| Beta-blocker approach | Migraine prevention through adrenergic pathway modulation | May be unsuitable with asthma, slow pulse, low blood pressure, or some cardiac conditions |
| Vestibular-symptom approach | Targets dizziness or inner-ear symptom patterns through a different mechanism | Benefit depends strongly on the underlying cause of vertigo |
Stugeron contains cinnarizine and is also associated with vestibular treatment, but its pharmacology and clinical selection differ from flunarizine. Vertin OD contains betahistine and is used in different vestibular contexts. Ciplar LA contains propranolol, a beta-blocker that may be used for migraine prevention in suitable patients.
These medicines should not be exchanged dose for dose. Propranolol can affect heart rate and breathing, while flunarizine can produce sedation, weight gain, depression, or movement symptoms. Betahistine and cinnarizine also have different clinical roles and contraindications [3].
What doctors say
In clinical practice, doctors usually assess Sibelium by looking for fewer migraine days, less severe attacks, reduced rescue-medicine use, or improved balance between episodes. One isolated headache-free day does not establish success. A consistent pattern across the treatment period is more meaningful.
A prescriber may choose flunarizine when migraine prevention is needed and the person does not have risk factors for depression, parkinsonism, problematic sedation, or falls. The same medicine may be less suitable when the person already has low energy, unexplained weight gain, or a strong sensitivity to sedating medicines.
Doctors also distinguish migraine-associated vertigo from other causes of dizziness. Inner-ear disease, low blood pressure, medication effects, neurological disorders, and visual problems can produce overlapping symptoms. Treatment works best when the underlying diagnosis is clear.
A medication review should include all prescription medicines, over-the-counter sleep products, antihistamines, alcohol intake, and recreational substances. Sedation is often additive rather than caused by one product alone.
What customers often ask
What should be discussed with a doctor before starting Sibelium?
A medical review should cover depression, Parkinson’s disease, tremor, stiffness, previous medicine reactions, liver problems, pregnancy, breastfeeding, and medicines that cause drowsiness. The TGA's 2024 guidance emphasises patient-specific risk assessment for medicines that can affect alertness or movement. Alcohol, sleep products, sedating antihistamines, and opioid pain medicines should also be disclosed. A clear diagnosis is needed when vertigo is the main symptom. Bring a current medicine list to the appointment.
What should happen if the expected result does not come?
Continue tracking migraine or vertigo episodes rather than increasing the amount independently. The European Medicines Agency's 2022 approach to preventive treatment supports reviewing benefit, tolerability, diagnosis, and adherence when the expected pattern does not improve. A clinician may reconsider the diagnosis, treatment duration, timing, or preventive strategy. Worsening depression, tremor, stiffness, severe sleepiness, or falls requires earlier review.
How does Sibelium differ from the closest alternatives?
Sibelium uses flunarizine, a calcium-channel-blocking mechanism, while propranolol uses beta-adrenergic blockade and betahistine is used in a different vestibular treatment pathway. The WHO's 2023 neurological medicines framework recognises that preventive treatments must be selected according to comorbidities and adverse-effect risks. Flunarizine may be limited by sedation, weight gain, depression, or movement symptoms. Propranolol may be limited by cardiovascular or respiratory conditions.
Is Sibelium suitable for older adults?
Older adults can use flunarizine only when the potential benefit outweighs risks such as sedation, falls, depression, stiffness, tremor, and parkinsonism. The TGA's 2024 guidance highlights the need for careful medicine review when a treatment can affect alertness or movement. Lower tolerance may become apparent through slower walking, daytime sleep, or confusion. New movement symptoms deserve prompt assessment rather than being dismissed as normal ageing.
Can people under 18 use Sibelium?
Use in people under 18 depends on the diagnosis, local prescribing practice, and specialist assessment. Paediatric migraine and vertigo require attention to causes, weight, developmental factors, and alternative treatments. WHO's 2023 paediatric prescribing principles support individual assessment rather than transferring an adult regimen to a child. Parents should report unusual sleepiness, mood changes, tremor, stiffness, or changes in school performance.
Can Sibelium be used during pregnancy or breastfeeding?
Pregnancy and breastfeeding require a specific risk–benefit discussion before flunarizine is started or continued. The TGA's 2024 recommendations support reviewing medicine exposure during pregnancy and lactation because treatment decisions depend on the condition, timing, and available alternatives. Do not begin, stop, or restart Sibelium for this reason without a prescriber’s plan. A pharmacist or doctor should also review any medicines used for acute migraine symptoms.
Do you offer anonymous delivery?
Your order will be securely packed and shipped within 24 hours. This is exactly what your package will look like (images of an actual item sent). It has the size and look of a regular private letter (24x11x0.7 cm) and its contents cannot be seen.
Comparison
Sources
- TGA (2024). Sibelium (flunarizine): Australian Product Information
- WHO (2023). Headache disorders
- NICE (2021). Headaches in over 12s: diagnosis and management (CG150)
How Buyers Rate Sibelium
Based on 4 reviews
Darren, 38 - (no city), used Sibelium for recurrent vestibular symptoms. The spinning episodes became less frequent, although he gained weight and found that increased appetite was difficult to manage.
1 Nov 2026Luke, 30 - (no city), stopped treatment after developing low mood and marked daytime sleepiness. He had expected an immediate effect during an attack and had not realised that Sibelium was intended for prevention.
5 Oct 2026Tom, 33 - (no city), found that migraine attacks became less disruptive after a consistent treatment period. He still needed a separate acute-treatment plan for breakthrough attacks.
A consistent treatment period 14 Oct 2026